SAN DIEGO, May 4, 2015 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update
Conference Call for the first quarter 2015 on Monday, May 11, 2015 at 4:30 p.m. ET/1:30 p.m.
PT. Dr. Helen Torley,
president and chief executive officer, will lead the call. On the
same date post-market, Halozyme will release financial results for
the first quarter 2015.
The call will be webcast live through the "Investors" section of
Halozyme's corporate website and a recording will be made available
following the close of the call. To access the webcast and
additional documents related to the call, please log on to
www.halozyme.com approximately fifteen minutes prior to the call to
register, download and install any necessary audio software. For
those without access to the Internet, the live call may be accessed
by phone by calling (866) 710-0179 (domestic callers) or (334)
323-7224 (international callers) using passcode 769890. A telephone
replay will be available shortly after the call by dialing (877)
919-4059 (domestic callers) or (334) 323-0140 (international
callers) using replay ID number 48722220.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, our investigational drug
PEGPH20, applies a unique approach to targeting solid tumors,
allowing increased access of co-administered cancer drug therapies
to the tumor. PEGPH20 is currently in development for
metastatic pancreatic cancer and non-small cell lung cancer and has
potential across additional cancers in combination with different
types of cancer therapies. In addition to its proprietary product
portfolio, Halozyme has established value-driving partnerships with
leading pharmaceutical companies including Roche, Pfizer, Janssen
and Baxter for its drug delivery
platform, ENHANZE™, which enables biologics and small molecule
compounds that are currently administered intravenously to be
delivered subcutaneously. Halozyme is headquartered in San
Diego. For more information on how we are innovating, visit
www.halozyme.com.
Contacts:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Jim Mazzola
Halozyme Therapeutics
858-704-8122
ir@halozyme.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/halozyme-to-host-first-quarter-2015-financial-results-conference-call-300076865.html
SOURCE Halozyme Therapeutics, Inc.